Tag: Generics
Biocon reports 30% revenue increase and ₹660 crore net profit in...
Biocon's Q1FY25 performance sees 117% EBITDA growth and ₹660 crore net profit, powered by strategic partnerships and biosimilar success
Biocon’s biosimilars revenue crosses milestone of US $1 Billion in FY...
The company garnered an overall revenue of Rs 15,621 Crore in FY24, marking a remarkable 35% growth compared to the previous year
Physicians lack consensus on patient choice between branded and generic drugs,...
Understanding these dynamics is pivotal for promoting informed decision-making and improving patient outcomes in medication management, according to the survey
Lupin appoints Dr Shahin Fesharaki as Global CSO
Dr. Fesharaki will be responsible for Lupin’s global research and development efforts across branded, generics and specialty products
Pricing pressures & regulatory scrutiny persist in US generics pharma industry:...
Some major Indian pharmaceutical companies reported sizeable impairment losses and also announced discontinuation of some products or segments due to lower earnings potential
India tops the chart for approved biosimilars & clinical trials surpassing...
The recent acts and policy changes like the Generic Drug User Fee Act (GDUFA) is expected to positively impact the generics manufacturers in India, deliberations at Pharma IPR India Conference revealed ..................................
India’s pharma industry & academia join hands to catalyze innovation in...
At the first CSIR-IPA Pharma Innovation Exchange Forum, the scientists come together to stimulate industry and academia exchange on pharmaceutical innovation knowledgebase and to forge future collaborations......................
Jubilant launches JUBI-R, its generic version of COVID-19 drug remdesivir in...
Jubilant Generics, a subsidiary of Jubilant Life Sciences has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of INR 4,700 per vial of 100 mg (lyophilized injection)........................
Dr Reddy’s Laboratories gets a new COO
Mr Erez Israeli, former President & CEO of Enzymotec has joined Dr Reddy’s Laboratories on April 2, 2018, as Chief Operating Officer and Global Head of Generics & PSAI, based out of Hyderabad...........
Amneal & Impax merger to create 5th biggest pharma generics firm...
Combined company to benefit from expanded generics product portfolio, premier diversified generics pipeline, broad R&D capabilities across dosage forms, high-quality and low-cost global manufacturing and distribution network, and enhanced financial foundation........